Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor

In several recent studies on metastatic breast cancer (MBC), ligand binding domain mutations of the estrogen receptor, which is coded by the ESR1 gene, were induced by long-term endocrine therapy and resulted in acquired endocrine therapy resistance and poor outcomes. Knowledge of the association be...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshima, Kaoru, Hayashida, Tetsu, Maeda, Hinako, Nakashoji, Ayako, Yokoe, Takamichi, Seki, Tomoko, Takahashi, Maiko, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377057/
https://www.ncbi.nlm.nih.gov/pubmed/32724363
http://dx.doi.org/10.3892/ol.2020.11669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377057/
https://www.ncbi.nlm.nih.gov/pubmed/32724363
http://dx.doi.org/10.3892/ol.2020.11669

Ejemplares similares